الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 99 |  |  |
| | | from | 99 | | |
Abstract
Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of cancer related death worldwide, affecting one million people per year. Currently, gastric cancer is still the seventh most common cause of cancer-related death in the United States and the prognosis of advanced gastric cancer remains poor. The aim of this prospective study is to assess the frequency of Her-2 over expression and amplification in Egyptian patients with gastric/gastro esophageal adenocarcinoma, in correlation with tumor histology, grade, size, and location.It was found that mean age was 55.3 years. There was slightly higher incidence in males (51.3% males). All of them had tumors of (diffuse histopathological type). Stage at presentation was as follows: Localized: 1(2.6%), locally advanced: 20(51.3%), Metastatic: 18 (46.2%).Her-2 was found to be overexpressed in four patients out of thirty-nine (10.3%).Her-2 negative patients had a significantly longer overall survival (9 months in Her-2 negative vs. 4 months in Her-2 positive) (p=0.01).Progression free survival (PFS) was significantly prolonged in Her-2 patients.Her-2 patients had a PFS of 8 months, vs. only 4 months in Her-2 positive patients (p=0.01). Median survival and PFS in locally advanced disease was significantly affected by the Her-2 status
(p=0.02).Neither median survival (p=0.8), nor PFS (p=0.5), were affected.
Conclusion: Her-2 is a prognostic factor in a small cohort of Egyptian patients with gastric/gastro esophageal carcinoma.